Advanced Search

 

Study ID Status Title Patient Level Data
AVA109941 Completed An open label single oral dose study in patients with mild Alzheimer's disease to assess the pharmacokinetics of extended release formulation of Rosiglitazone (RSG XR) in this population
AVD100521 Completed A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH) Study Listed on ClinicalStudyDataRequest.com
AVD102209 Completed A Randomized, Double-Blind, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
AVD104742 Completed Clinical evaluation of Rosiglitazone Malate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo - Study Listed on ClinicalStudyDataRequest.com
AVD105248 Completed Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Combination Therapy with Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study - Study Listed on ClinicalStudyDataRequest.com
AVD105720 Completed Clinical evaluation of Rosiglitazone Malate (BRL49653C) in patients with type 2 diabetes mellitus -Long-term study of Rosiglitazone Maleate- Study Listed on ClinicalStudyDataRequest.com
AVD111179 Completed A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
AVM100264 Completed A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin.
AVO105948 Completed A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management Study Listed on ClinicalStudyDataRequest.com
AVO108943 Completed A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Study Listed on ClinicalStudyDataRequest.com
AVR110549 Withdrawn A Bioequivalence Study with a Combination Tablet Formulation of rosiglitazone (RSG) and glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects
AVS101946 Completed A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
AVT105913 Completed A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment. Study Listed on ClinicalStudyDataRequest.com
AXO110461 Completed A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating single dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SB756050 in healthy volunteers and in subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
AXR107453 Completed An Open-Label, Randomized, two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg manufactured at two different sites in healthy volunteers in fasting conditions
AZ3100603 Completed A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with mild to moderate Alzheimer's disease
AZ3106242 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects with Mild to Moderate Alzheimer’s Disease
AZ3110291 Completed An open-label, randomised, two-part crossover study to assess the pharmacokinetics of a single dose of SB-742457 formulated as a capsule and a tablet in healthy elderly volunteers.
AZ3110865 Completed Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease
AZ3110866 Completed Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer’s disease
AZL30006 Completed A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.
B2A100517 Completed A randomised, double-blind, placebo-controlled, dose ascending, 4 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GW597901X in asthmatic subjects
B2C101762 Completed A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C104604 Completed A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M Study Listed on ClinicalStudyDataRequest.com
B2C106093 Completed Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444 Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.